Tune in at 6:00pm PT / 9:00pm ET on Wed. Nov. 30 when Neuralink’s Elon Musk reveals the latest advancements in Neuralink’s brain-computer interface technology.
Neuralink: Everything to Know About Elon Musk’s Brain Chip https://youtu.be/Qih2NJwt56c.
Elon Musk’s Next Neuralink Demo Is Coming. Here’s How to Watch https://cnet.co/3u81ixw.
Never miss a deal again! See CNET’s browser extension 
https://bit.ly/39Ub3bv.
#elonmusk #neuralink #cnetlive
Elon Musk and researchers at Neuralink reveal a series of demos showing the progress in the company’s brain-computer interface technologies.
Never miss a deal again! See CNET’s browser extension https://bit.ly/3lO7sOU
Follow us on TikTok: https://www.tiktok.com/@cnetdotcom.
Follow us on Instagram: https://www.instagram.com/cnet/
Follow us on Twitter: https://www.twitter.com/cnet.
Like us on Facebook: https://www.facebook.com/cnet
Pregnancy caused women to lose gray matter, and reshaped the brain’s “default mode network,” a set of brain regions that are most active when the brain is wandering.
Tune in on Nov 30 @ 6pm Pacific for an exciting update from Neuralink!
Join us in our mission to build generalized I/O devices for the brain → https://neuralink.com/careers
Elon Musk’s brain interface company is planning an event to show its latest efforts to connect brains and computers.
Summary: The adult brain contains millions of “silent synapses”, or immature connections between neurons that remain inactive until they are required for learning new information and storing new memories.
Source: MIT
MIT neuroscientists have discovered that the adult brain contains millions of “silent synapses” — immature connections between neurons that remain inactive until they’re recruited to help form new memories.
The treatment caused neurological changes, including a decrease in inflammation and an increase in functionality, according to the researchers.
A recent Tel Aviv University study found that pressure chamber therapy greatly improved social skills and the condition of the autistic brain. The research was carried out on autism animal models. The researchers discovered changes in the brain, including a decrease in neuroinflammation, which has been linked to autism. Furthermore, the social functioning of the animal models treated in the pressure chamber improved significantly. The success of the research has significant implications for the applicability and understanding of pressure chamber therapy as a treatment for autism.
Inbar Fischer, a Ph.D. student in Dr. Boaz Barak’s lab at Tel Aviv University’s Sagol School of Neuroscience and School of Psychological Sciences, led the team that made the discovery. The findings were recently published in the International Journal of Molecular Sciences.
Using modified MRI machines, physicists may have found quantum entanglement between the heart and brain If someone were to (theoretically) throw a wrench at your head, you might be able to catch it just in time to avoid a concussion. But how? Typically, for split-second reactions, we do not consciously decide to catch.
Alzheimer’s disease could soon be a distant memory.
A revolutionary new Alzheimer’s drug named lecanemab could mark a major breakthrough in the decades-long battle against the neurological disorder, according to eye-opening Phase 3 trials. The potentially game-changing dry runs transpired in May 2021, but the results were only published Tuesday in the New England Journal of Medicine.
“This first step is the hardest; I truly believe it represents the beginning of the end,” said Professor John Hardy, group leader at UK Dementia Research Institute at the University College London, describing the promising findings.
After statins, the next leading class of medications for managing cholesterol are PCSK9 inhibitors. These highly effective agents help the body pull excess cholesterol from the blood, but unlike statins, which are available as oral agents, PCSK9 inhibitors can only be administered as injections, creating barriers to their use.
Longevity. Technology: Having high cholesterol can increase the risk of heart and circulatory diseases such as heart attack, stroke and vascular dementia, but a new study from investigators at University Hospitals (UH) and Case Western Reserve University School of Medicine details an orally administered small-molecule drug that reduces PCSK9 levels and lowers cholesterol in animal models by 70%. Published in Cell Reports, the findings represent a previously unrecognised strategy for managing cholesterol and may also impact cancer treatments.
Cardiovascular disease ranking as the world’s number one killer, so it’s no surprise that a significant amount of research into potential therapeutic options is ongoing; just last week we looked at Cyclarity’s rationally-designed cyclodextrin molecules that remove arterial plaque by clearing the non-degradable oxidised cholesterol and which can be used in conjunction with statins for a broad-spectrum approach. Our report into Cyclarity’s new platform comes out next week, so stay tuned!
